Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Tumor Microenvironment and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AHR (Aryl Hydrocarbon Receptor) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Target Protein | AHR Recombinant Protein (Wild-Type & Mutant PAS-B Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Folding). Includes ligand-binding variants for selectivity counter-screens. |
View AHR Products |
| Gene Delivery | AHR Promise-ORF / Lentivirus Full-length ORF for stable cell lines and reporter assays. |
View AHR Products |
| Benchmark Ab | Anti-AHR (ChIP/Western Grade) Recombinant rabbit monoclonal positive control for target engagement and biochemical assays. |
View AHR Products |
| Validator | AHR siRNA Set Sequence-verified for knockdown verification in luciferase, Western blot, and qPCR assays. |
View AHR Products |
| Related Target: IDO1 | Indoleamine 2,3-Dioxygenase 1 (IDO1) Upstream kynurenine pathway enzyme; produces endogenous AHR agonist in the TME. Synergistic immuno-oncology node. |
View IDO1 Products |
| Related Target: ARNT | AHR Nuclear Translocator (ARNT) Obligate dimerization partner for AHR PPI and selectivity assays. Required for nuclear translocation and DNA binding. |
View ARNT Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Lack of stable, soluble AHR protein for in vitro binding; intracellular conformational complexity | Human/Mouse/Cyno AHR PAS-B & Full-Length proteins. >95% purity. Sequence Verified. Theoretical MW accuracy. |
| Off-target liability to HIF-1α/ARNT pathway; need for selectivity counter-screening | Matched ARNT & HIF-1α ortholog proteins for parallel SPR/AlphaScreen selectivity assays. |
| Cell-based target engagement & reporter cell line generation | AHR Lentivirus Premade Particles for stable HepG2 or XRE-Luc reporter lines; robust genomic integration. |
| Knockdown specificity confirmation & reliable controls | Validated AHR siRNA set + high-affinity monoclonal positive control antibody for Western blot & IHC standardization. |
Global Clinical Landscape & Future Outlook
The race for AHR therapeutics is intensifying, with major players shifting focus from traditional targets to modulating the tumor microenvironment (TME) and immune tolerance. As an intracellular ligand-dependent transcription factor, AHR sits at the intersection of xenobiotic metabolism and immune regulation. First-generation therapies (e.g., Ikena Oncology's IK-175, Bayer's BAY2416964) are in early clinical trials, primarily as antagonists combined with PD-1/PD-L1 checkpoint inhibitors for solid tumors. The next wave of R&D targets selective small molecule antagonists to reverse TME immunosuppression, and potent agonists for autoimmune and inflammatory indications (e.g., IBD). Emerging modalities include PROTAC degraders for refractory cancers. Combination regimens remain the key driver of pipeline expansion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | Ikena Oncology, Bayer | Solid Tumors (TME modulation) | Biochemical Binding Assay (need high-purity Recombinant Protein for SPR/TR-FRET) |
| Small Molecule Agonists | TapImmune, Various Biotech | Autoimmune, IBD | Reporter Gene Activation (need Lentivirus for Stable XRE-Luc Cell Line) |
| Pathway Modulators (PROTACs) | Early-stage Discovery | Refractory Cancers | Degradation Validation (need high-specificity Benchmark Antibodies for WB/IHC) |
Live AHR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: